Golimumab performs well in new evidence review
Golimumab, a tumor necrosis factor inhibitor that is used for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been found to work well and offers a good safety profile, a team outlines in Therapeutic Advances in Musculoskeletal Disease.
The experts looked at data from 12 trials that evaluated golimumab in inflammatory arthritis and the results bode well:
“Golimumab was found to be clinically effective and also have a good safety profile in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis based on data available from large studies.”
Click here to read the original research.
Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2018.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.